Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Synopsys shares dip on earnings, revenue miss

EditorRachael Rajan
Published 23/05/2024, 06:34 am
© Reuters.
SNPS
-

SUNNYVALE, Calif. - Synopsys, Inc. (NASDAQ:SNPS) reported a slight downturn in its stock price, falling 1.24% after announcing second-quarter financial results that fell short of Wall Street expectations.

The company's adjusted earnings per share (EPS) came in at $3.00, missing analysts' predictions by $0.05. Revenue also did not meet the anticipated target, registering at $1.46 billion against the consensus estimate of $1.51 billion.

The company's revenue for the quarter still saw a significant increase of approximately 15% compared to the same quarter last year, showcasing a strong year-over-year (YoY) growth. On a GAAP basis, net income for the second quarter of fiscal year 2024 was $299.1 million, or $1.92 per diluted share, compared to $275.6 million, or $1.78 per diluted share, for the same period the previous year. This reflects a solid performance despite the earnings and revenue shortfall relative to consensus estimates.

Synopsys' leadership attributed the robust quarterly performance to strong operational execution and business momentum. "We continued our strong operational execution and business momentum in Q2. Customers continue investing in Synopsys solutions to maximize their R&D and power their future innovations for this era of pervasive intelligence," said Sassine Ghazi, president and CEO of Synopsys.

Looking ahead, Synopsys provided guidance for the third quarter with revenue expected to range between $1.505 billion and $1.535 billion. The midpoint of this guidance, $1.52 billion, is slightly above the analyst consensus estimate of $1.51 billion.

For the full fiscal year 2024, the company anticipates revenue to be between $6.090 billion and $6.150 billion. The midpoint of this range, $6.12 billion, also surpasses the consensus estimate. Adjusted EPS guidance for the third quarter is set at $3.25 to $3.30, with the midpoint of $3.275 slightly below the consensus estimate of $3.30.

The company's CFO, Shelagh Glaser, expressed confidence in the business outlook, stating, "Synopsys' strong Q2 results were driven by our team's relentless focus on execution, our leading technology that is mission-critical to customers, and our resilient business model. We remain confident in our business, and as a result, we are again raising our full-year targets for revenue and adjusted EPS."

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.